{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:41:42Z","timestamp":1776238902565,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Survival with Pancreatic Cancer Foundation","award":["OVIT17-06"],"award-info":[{"award-number":["OVIT17-06"]}]},{"name":"the Survival with Pancreatic Cancer Foundation","award":["OVIT17-06"],"award-info":[{"award-number":["OVIT17-06"]}]},{"name":"the Survival with Pancreatic Cancer Foundation","award":["OVIT17-06"],"award-info":[{"award-number":["OVIT17-06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Balancing therapeutic benefit and treatment burden remains a major challenge in administering FOLFIRINOX for advanced pancreatic ductal adenocarcinoma (PDAC). More than 60% of patients experience grade\u2009\u2265\u20093 adverse events (AEs), and only about 30% achieve a tumour response. This study examines the value of FOLFIRINOX chemotherapy by contextualising treatment efficacy, toxicity, and durability of response within ethical, financial, and person-centred frameworks. The aim is to support shared decision-making and optimise clinical outcomes and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with advanced PDAC receiving palliative FOLFIRINOX were included. Radiologic response was assessed using RECIST 1.1 at sequential time points during and after therapy. Patients were classified as having either progressive disease or disease control, the latter encompassing complete response, partial response, and stable disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Amongst 84 advanced PDAC patients, 14 (17%) discontinued FOLFIRINOX before completing four cycles due to grade\u2009\u2265\u20093 AEs. Another four patients (5%) terminated FOLFIRINOX treatment after four cycles despite exhibiting disease control. Overall, 36 (43%) patients had at least one FOLFIRINOX-related grade\u2009\u2265\u20093 AE. Amongst the 66 patients who completed\u2009\u2265\u20094 cycles, 52 (79%) achieved disease control at FOLFIRINOX completion. However, disease control declined rapidly after therapy, falling to 41% at 6 months, 21% at 1 year, and 11% at 2 years. LAPC patients achieved disease control more frequently than patients with metastatic disease. Nevertheless, both groups experienced steep declines in disease control over time, from 85% and 69% at treatment completion to 32% and 4% at 1 year in LAPC and metastatic PDAC, respectively. Overall, 36 patients (55%) received subsequent systemic or locoregional therapies, most commonly gemcitabine\/nab-paclitaxel (6%), SBRT (17%), or immunotherapy combined with SBRT (11%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Whilst FOLFIRINOX achieves high initial disease control in advanced PDAC, its benefit is limited by substantial toxicity and poor durability. Only a minority of patients maintain disease control beyond 6 months, which is strongly associated with improved survival. These findings suggest a need to redefine \u2018valuable FOLFIRINOX chemotherapy\u2019 to encompass not only initial response but also sustained disease control, toxicity management, and shared decision-making to optimise the benefit of FOLFIRINOX for patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10568-3","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:01:45Z","timestamp":1774515705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life"],"prefix":"10.1007","volume":"34","author":[{"given":"Gaby J.","family":"Strijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniek E.","family":"van Diepen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A. C.","family":"Rietjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte C. M.","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Stiggelbout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein Y. V.","family":"Homs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casper H. J.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casper W. F.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"10568_CR1","doi-asserted-by":"publisher","unstructured":"Stoop TF, Javed AA, Oba A, Korkeamp BG, Seufferlein T, Wilmink JW, et al (2025) Pancreatic cancer. Lancet 405(10485):1182-1202. https:\/\/doi.org\/10.1016\/S0140-6736(25)00261-2","DOI":"10.1016\/S0140-6736(25)00261-2"},{"key":"10568_CR2","doi-asserted-by":"publisher","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A, et al (2026) Cancer statistics, 2026. CA Cancer J Clin 76(1):e70043. https:\/\/doi.org\/10.3322\/caac.70043","DOI":"10.3322\/caac.70043"},{"issue":"11","key":"10568_CR3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241354","volume":"15","author":"M Schlueter","year":"2020","unstructured":"Schlueter M, Chan K, Lasry R, Price M (2020) The cost of cancer - a comparative analysis of the direct medical costs of cancer and other major chronic diseases in Europe. PLoS One 15(11):e0241354","journal-title":"PLoS One"},{"issue":"12","key":"10568_CR4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/jnci\/djab192","volume":"113","author":"KR Yabroff","year":"2021","unstructured":"Yabroff KR, Mariotto A, Tangka F, Zhao J, Islami F, Sung H et al (2021) Annual report to the nation on the status of cancer, part 2: patient economic burden associated with cancer care. J Natl Cancer Inst 113(12):1670\u20131682","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10568_CR5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17(6):801\u2013810","journal-title":"Lancet Oncol"},{"issue":"1","key":"10568_CR6","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7010007","volume":"7","author":"S Thibodeau","year":"2018","unstructured":"Thibodeau S, Voutsadakis IA (2018) FOLFIRINOX chemotherapy in metastatic pancreatic cancer: a systematic review and meta-analysis of retrospective and phase II studies. J Clin Med 7(1):7","journal-title":"J Clin Med"},{"issue":"7","key":"10568_CR7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ueg2.12123","volume":"9","author":"P Michl","year":"2021","unstructured":"Michl P, Lohr M, Neoptolemos JP, Capurso G, Rebours V, Malats N et al (2021) UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: prevent, detect, and treat the disease earlier and better. United European Gastroenterol J 9(7):860\u201371","journal-title":"United European Gastroenterol J"},{"issue":"19","key":"10568_CR8","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825","journal-title":"N Engl J Med"},{"issue":"9","key":"10568_CR9","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamasurg.2020.2286","volume":"155","author":"G Perri","year":"2020","unstructured":"Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D et al (2020) Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-Paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. JAMA Surg 155(9):832\u2013839","journal-title":"JAMA Surg"},{"key":"10568_CR10","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8549487","volume":"2022","author":"F van der Sijde","year":"2022","unstructured":"van der Sijde F, van Dam JL, Groot Koerkamp B, Haberkorn BCM, Homs MYV, Mathijssen D et al (2022) Treatment response and conditional survival in advanced pancreatic cancer patients treated with FOLFIRINOX: a multicenter cohort study. J Oncol 2022:8549487","journal-title":"J Oncol"},{"issue":"16","key":"10568_CR11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015341","volume":"98","author":"A Ulusakarya","year":"2019","unstructured":"Ulusakarya A, Teyar N, Karaboue A, Haydar M, Krimi S, Biondani P et al (2019) Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) 98(16):e15341","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10568_CR12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"5","key":"10568_CR13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jnci\/djac018","volume":"114","author":"QP Janssen","year":"2022","unstructured":"Janssen QP, van Dam JL, Doppenberg D, Prakash LR, van Eijck CHJ, Jarnagin WR et al (2022) FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the trans-atlantic pancreatic surgery consortium. J Natl Cancer Inst 114(5):695\u2013703","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10568_CR14","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO-24-02210","volume":"43","author":"M Ducreux","year":"2025","unstructured":"Ducreux M, Desgrippes R, Rinaldi Y, Di Fiore F, Guimbaud R, Evesque L et al (2025) PRODIGE 29-UCGI 26 (NEOPAN): a phase III randomized trial comparing chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic carcinoma. J Clin Oncol 43(20):2255\u20132264","journal-title":"J Clin Oncol"},{"issue":"12","key":"10568_CR15","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","volume":"25","author":"L Mastrantoni","year":"2024","unstructured":"Mastrantoni L, Chiaravalli M, Spring A, Beccia V, Di Bello A, Bagala C et al (2024) Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis. Lancet Oncol 25(12):1655\u20131665","journal-title":"Lancet Oncol"},{"issue":"6","key":"10568_CR16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/bjc.2016.222","volume":"115","author":"MK Chllamma","year":"2016","unstructured":"Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L et al (2016) FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer 115(6):649\u2013654","journal-title":"Br J Cancer"},{"issue":"13","key":"10568_CR17","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.7150\/jca.16279","volume":"7","author":"SJ Rombouts","year":"2016","unstructured":"Rombouts SJ, Mungroop TH, Heilmann MN, van Laarhoven HW, Busch OR, Molenaar IQ et al (2016) FOLFIRINOX in locally advanced and metastatic pancreatic cancer: a single centre cohort study. J Cancer 7(13):1861\u20131866","journal-title":"J Cancer"},{"issue":"12","key":"10568_CR18","volume":"12","author":"L Haggstrom","year":"2024","unstructured":"Haggstrom L, Chan WY, Nagrial A, Chantrill LA, Sim HW, Yip D et al (2024) Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 12(12):CD011044","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10568_CR19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/MPA.0000000000001837","volume":"50","author":"B Caron","year":"2021","unstructured":"Caron B, Reimund JM, Ben Abdelghani M, Sondag D, Noirclerc M, Duclos B et al (2021) Survival and predictive factors of chemotherapy with FOLFIRINOX as first-line therapy in metastatic pancreatic cancer: a retrospective multicentric analysis. Pancreas 50(6):803\u2013806","journal-title":"Pancreas"},{"issue":"29","key":"10568_CR20","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1200\/JCO.20.03329","volume":"39","author":"L Dahan","year":"2021","unstructured":"Dahan L, Williet N, Le Malicot K, Phelip JM, Desrame J, Bouche O et al (2021) Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial. J Clin Oncol 39(29):3242\u20133250","journal-title":"J Clin Oncol"},{"issue":"4","key":"10568_CR21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejrad.2012.12.002","volume":"82","author":"C Cassinotto","year":"2013","unstructured":"Cassinotto C, Cortade J, Belleann\u00e9e G, Lapuyade B, Terrebonne E, Vendrely V et al (2013) An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol 82(4):589\u2013593","journal-title":"Eur J Radiol"},{"issue":"1","key":"10568_CR22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","volume":"261","author":"CR Ferrone","year":"2015","unstructured":"Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261(1):12\u201317","journal-title":"Ann Surg"},{"issue":"12","key":"10568_CR23","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1007\/s00261-020-02723-z","volume":"45","author":"ZJ Wang","year":"2020","unstructured":"Wang ZJ, Arif-Tiwari H, Zaheer A, Ameli S, Bhosale PR, Do RK et al (2020) Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. Abdom Radiol 45(12):4273\u20134289","journal-title":"Abdom Radiol"},{"issue":"2","key":"10568_CR24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1470-2045(08)70001-9","volume":"9","author":"V Hess","year":"2008","unstructured":"Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T et al (2008) CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 9(2):132\u2013138","journal-title":"Lancet Oncol"},{"key":"10568_CR25","doi-asserted-by":"crossref","unstructured":"Dekker EN, van Klaveren D, Verkolf EMM, de Wilde RF, Besselink MG, O'Reilly EM, et al. (2025) Carbohydrate antigen 19\u20139 (CA19\u20139) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort study. Br J Surg. 112(2).","DOI":"10.1093\/bjs\/znaf011"},{"key":"10568_CR26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2022.12.024","volume":"181","author":"CWF van Eijck","year":"2023","unstructured":"van Eijck CWF, de Koning W, van der Sijde F, Moskie M, Groot Koerkamp B, Homs MYV et al (2023) A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. Eur J Cancer 181:119\u2013134","journal-title":"Eur J Cancer"},{"key":"10568_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010093","author":"F van der Sijde","year":"2019","unstructured":"van der Sijde F, Vietsch EE, Mustafa DAM, Besselink MG, Groot Koerkamp B, van Eijck CHJ (2019) Circulating biomarkers for prediction of objective response to chemotherapy in pancreatic cancer patients. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11010093","journal-title":"Cancers (Basel)"},{"key":"10568_CR28","doi-asserted-by":"publisher","unstructured":"van der Sijde F, Vietsch EE, Mustafa DAM, Besselink MG, Groot Koerkamp B, van Eijck CHJ (2019) Circulating biomarkers for prediction of objective response to chemotherapy in pancreatic cancer patients. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11010093","DOI":"10.3390\/cancers11010093"},{"key":"10568_CR29","volume":"49","author":"CWF van Eijck","year":"2024","unstructured":"van Eijck CWF, Sabroso-Lasa S, Strijk GJ, Mustafa DAM, Fellah A, Koerkamp BG et al (2024) A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy. Neoplasia 49:100975","journal-title":"Neoplasia"},{"issue":"3","key":"10568_CR30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.pan.2025.02.007","volume":"25","author":"SS Kim","year":"2025","unstructured":"Kim SS, Kim S, Jo JH, Lee HS, Chung JJ, Bang S et al (2025) Early response evaluation using CT and CA 19-9 in patients with pancreatic cancer of all stages undergoing first-line FOLFIRINOX treatment. Pancreatology 25(3):377\u2013384","journal-title":"Pancreatology"},{"issue":"11","key":"10568_CR31","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.21873\/anticanres.17836","volume":"45","author":"YK Cheon","year":"2025","unstructured":"Cheon YK, Lee SH, Kim DW, Kim JH, Kim SM, Lee TY et al (2025) Clearance of TP53 mutations in ctDNA reflects therapeutic response in advanced pancreatic cancer patients. Anticancer Res 45(11):4891\u20134907","journal-title":"Anticancer Res"},{"issue":"1","key":"10568_CR32","volume":"16","author":"JJ Knox","year":"2025","unstructured":"Knox JJ, Jang GH, Grant RC, Zhang A, Ma L, Elimova E et al (2025) Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Nat Commun 16(1):5919","journal-title":"Nat Commun"},{"issue":"9","key":"10568_CR33","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41416-023-02170-9","volume":"128","author":"A Dayimu","year":"2023","unstructured":"Dayimu A, Di Lisio L, Anand S, Roca-Carreras I, Qian W, Al-Mohammad A et al (2023) Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. Br J Cancer 128(9):1672\u20131680","journal-title":"Br J Cancer"},{"issue":"1","key":"10568_CR34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-08297-z","volume":"7","author":"M Del Re","year":"2017","unstructured":"Del Re M, Vivaldi C, Rofi E, Vasile E, Miccoli M, Caparello C et al (2017) Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci Rep 7(1):7931","journal-title":"Sci Rep"},{"issue":"1","key":"10568_CR35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0891-4222(94)00028-8","volume":"16","author":"D Felce","year":"1995","unstructured":"Felce D, Perry J (1995) Quality of life: its definition and measurement. Res Dev Disabil 16(1):51\u201374","journal-title":"Res Dev Disabil"},{"issue":"5","key":"10568_CR36","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.pec.2016.12.019","volume":"100","author":"CM Bastemeijer","year":"2017","unstructured":"Bastemeijer CM, Voogt L, van Ewijk JP, Hazelzet JA (2017) What do patient values and preferences mean? A taxonomy based on a systematic review of qualitative papers. Patient Educ Couns 100(5):871\u2013881","journal-title":"Patient Educ Couns"},{"issue":"5","key":"10568_CR37","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1002\/cam4.5336","volume":"12","author":"CEJ Vrinzen","year":"2023","unstructured":"Vrinzen CEJ, Bloemendal HJ, Stuart E, Makady A, van Agthoven M, Koster M et al (2023) Cancer treatments touch a wide range of values that count for patients and other stakeholders: what are the implications for decision-making? Cancer Med 12(5):6105\u20136116","journal-title":"Cancer Med"},{"issue":"3","key":"10568_CR38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/fon-2021-0260","volume":"18","author":"P Dhakal","year":"2022","unstructured":"Dhakal P, Wichman CS, Pozehl B, Weaver M, Fisher AL, Vose J et al (2022) Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age? Future Oncol 18(3):311\u2013321","journal-title":"Future Oncol"},{"issue":"Suppl 1","key":"10568_CR39","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1111\/j.1524-4733.2005.00073.x","volume":"8","author":"L Abetz","year":"2005","unstructured":"Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-Maynard D et al (2005) Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing. Value Health 8(Suppl 1):S41-53","journal-title":"Value Health"},{"issue":"5","key":"10568_CR40","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1089\/jpm.2021.0187","volume":"25","author":"V Chung","year":"2022","unstructured":"Chung V, Sun V, Ruel N, Smith TJ, Ferrell BR (2022) Improving palliative care and quality of life in pancreatic cancer patients. J Palliat Med 25(5):720\u2013727","journal-title":"J Palliat Med"},{"key":"10568_CR41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103068","volume":"80","author":"AM Gehrels","year":"2025","unstructured":"Gehrels AM, Vissers PAJ, Sprangers MAG, Fijnheer NM, Pijnappel EN, van der Geest LG et al (2025) Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. EClinicalMedicine 80:103068","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10568_CR42","first-page":"2407","volume":"30","author":"F van der Sijde","year":"2022","unstructured":"van der Sijde F, Schafthuizen L, van \u2019t Land FR, Moskie M, van Laarhoven HWM, van Dijk M et al (2022) Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. Support Care Cancer 30(3):2407\u201315","journal-title":"Support Care Cancer"},{"issue":"9","key":"10568_CR43","doi-asserted-by":"crossref","DOI":"10.1002\/pon.70260","volume":"34","author":"J Bergqvist","year":"2025","unstructured":"Bergqvist J, Nordberg JH, Wode K, Sunde B, Fransson P, Bernhardson BM (2025) Living with advanced pancreatic cancer: patients\u2019 experiences of daily life. Psychooncology 34(9):e70260","journal-title":"Psychooncology"},{"issue":"3","key":"10568_CR44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0643","volume":"3","author":"N Marschner","year":"2020","unstructured":"Marschner N, Zacharias S, Lordick F, Hegewisch-Becker S, Martens U, Welt A et al (2020) Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer. JAMA Netw Open 3(3):e200643","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10568_CR45","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jamaoncol.2016.0931","volume":"2","author":"H Kumar","year":"2016","unstructured":"Kumar H, Fojo T, Mailankody S (2016) An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol 2(9):1238\u20131240","journal-title":"JAMA Oncol"},{"key":"10568_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20064895","author":"E Cipora","year":"2023","unstructured":"Cipora E, Czerw A, Partyka O, Pajewska M, Badowska-Kozakiewicz A, Fudalej M et al (2023) Quality of life in patients with pancreatic cancer-a literature review. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph20064895","journal-title":"Int J Environ Res Public Health"},{"key":"10568_CR47","doi-asserted-by":"publisher","unstructured":"Cipora E, Czerw A, Partyka O, Pajewska M, Badowska-Kozakiewicz A, Fudalej M et al (2023) Quality of life in patients with pancreatic cancer-a literature review. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph20064895","DOI":"10.3390\/ijerph20064895"},{"issue":"2","key":"10568_CR48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.pec.2004.10.012","volume":"59","author":"JA Rietjens","year":"2005","unstructured":"Rietjens JA, van der Heide A, Voogt E, Onwuteaka-Philipsen BD, van der Maas PJ, van der Wal G (2005) Striving for quality or length at the end-of-life: attitudes of the Dutch general public. Patient Educ Couns 59(2):158\u2013163","journal-title":"Patient Educ Couns"},{"issue":"12","key":"10568_CR49","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/sj.bjc.6601445","volume":"89","author":"CG Koedoot","year":"2003","unstructured":"Koedoot CG, de Haan RJ, Stiggelbout AM, Stalmeier PF, de Graeff A, Bakker PJ et al (2003) Palliative chemotherapy or best supportive care? A prospective study explaining patients\u2019 treatment preference and choice. Br J Cancer 89(12):2219\u20132226","journal-title":"Br J Cancer"},{"issue":"9","key":"10568_CR50","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S1470-2045(17)30582-X","volume":"18","author":"JAC Rietjens","year":"2017","unstructured":"Rietjens JAC, Sudore RL, Connolly M, van Delden JJ, Drickamer MA, Droger M et al (2017) Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care. Lancet Oncol 18(9):e543\u2013e551","journal-title":"Lancet Oncol"},{"issue":"17","key":"10568_CR51","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1002\/cam4.4145","volume":"10","author":"IPM Griffioen","year":"2021","unstructured":"Griffioen IPM, Rietjens JAC, Melles M, Snelders D, Homs MYV, van Eijck CH et al (2021) The bigger picture of shared decision making: a service design perspective using the care path of locally advanced pancreatic cancer as a case. Cancer Med 10(17):5907\u20135916","journal-title":"Cancer Med"},{"issue":"1","key":"10568_CR52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13187-018-1444-3","volume":"35","author":"K Adamowicz","year":"2020","unstructured":"Adamowicz K, Janiszewska J, Lichodziejewska-Niemierko M (2020) Prognostic value of patient knowledge of cancer on quality of life in advanced lung cancer during chemotherapy. J Cancer Educ 35(1):93\u201399","journal-title":"J Cancer Educ"},{"issue":"27\u201328","key":"10568_CR53","first-page":"471","volume":"116","author":"K Steindorf","year":"2019","unstructured":"Steindorf K, Clauss D, Tjaden C, Hackert T, Herbolsheimer F, Bruckner T et al (2019) Quality of life, fatigue, and sleep problems in pancreatic cancer patients\u2014a randomized trial on the effects of exercise. Dtsch Arztebl Int 116(27\u201328):471\u2013478","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"10568_CR54","volume":"31","author":"E Chong","year":"2022","unstructured":"Chong E, Crowe L, Mentor K, Pandanaboyana S, Sharp L (2022) Systematic review of caregiver burden, unmet needs and quality-of-life among informal caregivers of patients with pancreatic cancer. Support Care Cancer 31(1):74","journal-title":"Support Care Cancer"},{"issue":"5","key":"10568_CR55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/bmjebm-2022-112168","volume":"28","author":"A Stiggelbout","year":"2023","unstructured":"Stiggelbout A, Griffioen I, Brands J, Melles M, Rietjens J, Kunneman M et al (2023) Metro mapping: development of an innovative methodology to co-design care paths to support shared decision making in oncology. BMJ Evid Based Med 28(5):291\u2013294","journal-title":"BMJ Evid Based Med"},{"key":"10568_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/nu11051145","author":"SH Kim","year":"2019","unstructured":"Kim SH, Lee SM, Jeung HC, Lee IJ, Park JS, Song M et al (2019) The effect of nutrition intervention with oral nutritional supplements on pancreatic and bile duct cancer patients undergoing chemotherapy. Nutrients. https:\/\/doi.org\/10.3390\/nu11051145","journal-title":"Nutrients"},{"key":"10568_CR57","doi-asserted-by":"publisher","unstructured":"Kim SH, Lee SM, Jeung HC, Lee IJ, Park JS, Song M et al (2019) The effect of nutrition intervention with oral nutritional supplements on pancreatic and bile duct cancer patients undergoing chemotherapy. Nutrients. https:\/\/doi.org\/10.3390\/nu11051145","DOI":"10.3390\/nu11051145"},{"issue":"2","key":"10568_CR58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pan.2019.01.014","volume":"19","author":"J Giuliani","year":"2019","unstructured":"Giuliani J, Bonetti A (2019) FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic cancer. Pancreatology 19(2):325\u2013330","journal-title":"Pancreatology"},{"issue":"10","key":"10568_CR59","first-page":"1367","volume":"27","author":"AA Kharat","year":"2021","unstructured":"Kharat AA, Nelson R, Au T, Biskupiak J (2021) Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials. J Manag Care Spec Pharm 27(10):1367\u20131375","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"10568_CR60","volume":"5","author":"MA Ingram","year":"2022","unstructured":"Ingram MA, Lauren BN, Pumpalova Y, Park J, Lim F, Bates SE et al (2022) Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable\/locally advanced pancreatic cancer patients. Cancer Rep 5(9):e1565","journal-title":"Cancer Rep"},{"issue":"7","key":"10568_CR61","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1634\/theoncologist.2018-0114","volume":"24","author":"JG Choi","year":"2019","unstructured":"Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P et al (2019) Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: results of a decision analysis. Oncologist 24(7):945\u2013954","journal-title":"Oncologist"},{"issue":"1","key":"10568_CR62","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.3747\/co.21.1327","volume":"21","author":"CL Attard","year":"2014","unstructured":"Attard CL, Brown S, Alloul K, Moore MJ (2014) Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Curr Oncol 21(1):e41-51","journal-title":"Curr Oncol"},{"issue":"4","key":"10568_CR63","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/13696998.2016.1269015","volume":"20","author":"M Gharaibeh","year":"2017","unstructured":"Gharaibeh M, McBride A, Bootman JL, Patel H, Abraham I (2017) Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. J Med Econ 20(4):345\u2013352","journal-title":"J Med Econ"},{"issue":"4","key":"10568_CR64","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14737167.2020.1812386","volume":"21","author":"J Cui","year":"2021","unstructured":"Cui J, Zhang X, Qu S, Wang L (2021) Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in China. Expert Rev Pharmacoecon Outcomes Res 21(4):691\u2013697","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10568_CR65","doi-asserted-by":"crossref","first-page":"294","DOI":"10.5301\/tj.5000499","volume":"2016","author":"J Zhou","year":"2016","unstructured":"Zhou J, Zhao R, Wen F, Zhang P, Wu Y, Tang R et al (2016) Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Tumori 2016(3):294\u2013300","journal-title":"Tumori"},{"issue":"4","key":"10568_CR66","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jval.2016.11.002","volume":"20","author":"D Coyle","year":"2017","unstructured":"Coyle D, Ko YJ, Coyle K, Saluja R, Shah K, Lien K et al (2017) Cost-effectiveness analysis of systemic therapies in advanced pancreatic cancer in the Canadian health care system. Value Health 20(4):586\u2013592","journal-title":"Value Health"},{"issue":"1 Suppl","key":"10568_CR67","first-page":"S11","volume":"25","author":"SA Soefje","year":"2019","unstructured":"Soefje SA (2019) Managing the economic impact of advanced pancreatic cancer. Am J Manag Care 25(1 Suppl):S11\u2013S16","journal-title":"Am J Manag Care"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10568-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:42:37Z","timestamp":1776235357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10568-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10568"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10568-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participants in this study originated from the iKnowIT prospective cohort study (Dutch trial register NL7522). The iKnowIT study adhered to the Declaration of Helsinki and was approved in February 2019 by the Ethics Committees of the Erasmus MC (MEC-2018\u2013087), the Amsterdam University Medical Centre (L18-053), and Maasstad Hospital (L2018095) in the Netherlands. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"372"}}